Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Taysha Gene Therapies Inc.

Headquarters: Dallas, TX, United States of America
Year Founded: 2019
Status: Public
Industry Sector: HealthTechnology
CEO: Sean P. Nolan
Number Of Employees: 73
Enterprise Value: $357,197,548
PE Ratio: -4.52
Exchange/Ticker 1: NASDAQ:TSHA
Exchange/Ticker 2: N/A
Latest Market Cap: $352,603,392

BioCentury | Nov 13, 2024
Product Development

Adverse event casts shadow over Neurogene’s Rett syndrome readout

BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Jun 29, 2024
Finance

Public Equity Report: Alumis slides after downsized IPO

Plus: Offerings by Zealand, Savara and Taysha; Savara’s PIPE; Grail reaches NASDAQ after Illumina separation
BioCentury | May 31, 2024
Regulation

Debating a new pathway for ultrarare 

Woodcock, patient advocates, biotech leaders call for reforms
BioCentury | Mar 20, 2024
Product Development

Non-profit biotech aims to revive stalled ultrarare therapies

Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model 
BioCentury | Mar 5, 2024
Management Tracks

Promotions at Ally Bridge

Plus: Schreyer named CTO at Anagenex, and updates from 4M, Sitryx and Apollomics
BioCentury | Oct 18, 2023
Management Tracks

eTheRNA names Sagaert CEO, Dekkers as chairman

Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
BioCentury | Sep 20, 2023
Finance

Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch

Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek 
BioCentury | Aug 15, 2023
Deals

Aug. 14 Quick Takes: Second bidder drove up price in Biogen-Reata deal

Plus: Approval for Pfizer’s MM bispecific and updates from Harmony-Zynerba, One Bio-Hengrui, Taysha, Arcturus, BioXcel 
BioCentury | Jul 21, 2023
Management Tracks

Ann Lee-Karlon named CEO of EpiBiologics

Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio 
BioCentury | Jul 10, 2023
Deals

July 10 Quick Takes: Astellas licenses 4D’s AAV vector

Plus: J&J partners with Nanobiotix and updates from CMS, WuXi, BeiGene and more
Items per page:
1 - 10 of 26